Maci
matrix-applied characterised autologous cultured chondrocytes
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Maci has expired following the marketing-authorisation holder’s decision not to pursue the renewal of the marketing authorisation.
This EPAR was last updated on 05/07/2018
Authorisation details
| Product details | |
|---|---|
| Name |
Maci
|
| Agency product number |
EMEA/H/C/002522
|
| Active substance |
autologous cultured chondrocytes
|
| International non-proprietary name (INN) or common name |
matrix-applied characterised autologous cultured chondrocytes
|
| Therapeutic area (MeSH) |
Fractures, Cartilage
|
| Anatomical therapeutic chemical (ATC) code |
M09AX02
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Vericel Denmark ApS
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
27/06/2013
|
| Contact address |
Amaliegade 10,
DK-1256 Copenhagen K Denmark |
Product information
01/07/2018 Maci - EMEA/H/C/002522 - IAIN/0009
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pharmacotherapeutic group
Other drugs for disorders of the musculo-skeletal system
Therapeutic indication
Therapeutic indication
Repair of symptomatic cartilage defects of the knee.